框架：唐朝《手把手教你读财报》+ Schilit《Financial Shenanigans》+ Beneish M-Score
核心理念："财报是用来排除企业的"
数据来源：SEC EDGAR 10-K原文 + Yahoo Finance
❌ 评级F——现金覆盖和商誉扩张
一句话：强生的F评级来自两项失败——$201亿现金仅覆盖$479亿债务的42%，$992亿商誉+无形资产等于$815亿权益基数的122%。两项关注增加细节：应收增长15.7%超过营收6.0%，其他非流动资产增长25.9%。底层业务异常强劲：营收增长6.0%到$942亿、净利润$268亿、经营现金流$245亿、债务/EBITDA 1.2x、M-Score -2.26（刚进入安全区）。资产负债表杠杆是FY2025 $175亿并购支出的直接后果——主要是$146亿的Intra-Cellular Therapies收购案，把CAPLYTA带入创新医药组合。这是一个在一家原本无瑕的医药康集团上的并购驱动杠杆故事。
| 项目 | 结果 |
|---|---|
| ❌ 排除项 | **2** 项（现金 vs 债务、商誉+无形） |
| ⚠️ 关注项 | **2** 项（应收 vs 营收、软资产增长） |
| 已检查 | **17/18** 项（D4 N/A） |
| Beneish M-Score | **-2.26**（安全区边缘） |
| 审计师 | PricewaterhouseCoopers LLP（无保留意见，2项关键审计事项：美国创新医药回扣准备金；滑石粉诉讼或有事项） |
| 报告期 | 2025年度 |
一、两大全球分部：创新医药和医疗科技
强生在2023年Kenvue消费健康分拆后运营两个报告分部：
创新医药（Innovative Medicine）——FY2025销售额$604亿，同比增长6.0%。MD&A："Innovative Medicine segment sales in 2025 were $60.4 billion, an increase of 6.0% from 2024, which included operational growth of 5.3% and a positive currency impact of 0.7%. U.S. sales were $36.3 billion, an increase of 7.0%."
医疗科技（MedTech）——FY2025销售额$338亿，同比增长6.1%。MD&A："MedTech segment sales in 2025 were $33.8 billion, an increase of 6.1% from 2024, which included operational growth of 5.4% and a positive currency impact of 0.7%. U.S. sales were $17.4 billion."
全球销售额合计$942亿反映了平衡的地域组合：$538亿美国（57%）和$404亿国际（43%）。
STELARA下滑和肿瘤学引擎
FY2025业绩包含一个重大负面：STELARA失去专利独占权、面临生物类似药竞争。MD&A："In the fiscal year 2025, the negative impact of the STELARA sales decline, due to biosimilar competition, was approximately 6.2%, 7.6% and 4.4% on worldwide, U.S. and international operational sales, respectively."
| 免疫学产品 | FY2025 | FY2024 | 变化 |
|---|---|---|---|
| STELARA | $6,078M | $10,361M | -41.3% |
| TREMFYA | $5,155M | $3,670M | +40.5% |
| REMICADE | $1,768M | $1,605M | +10.2% |
| SIMPONI/SIMPONI ARIA | $2,668M | $2,190M | +21.8% |
| **免疫学合计** | **$15,728M** | **$17,828M** | **-11.8%** |
STELARA一年内损失了$43亿销售额（从$104亿到$61亿）。TREMFYA增长$15亿部分抵消了下滑，但免疫学总销售额下降11.8%。
肿瘤学是突出的增长引擎：
| 肿瘤学产品 | FY2025 | FY2024 | 变化 |
|---|---|---|---|
| DARZALEX | $14,351M | $11,670M | +23.0% |
| ERLEADA | $3,574M | $2,999M | +19.2% |
| CARVYKTI | $1,887M | $963M | +95.9% |
| IMBRUVICA | $2,823M | $3,038M | -7.1% |
| RYBREVANT/LAZCLUZE | $734M | $327M | +124% |
| TALVEY | $463M | $287M | +61.3% |
| TECVAYLI | $670M | $549M | +22.1% |
| **肿瘤学合计** | **$25,380M** | **$20,781M** | **+22.1%** |
MD&A："Oncology products achieved sales of $25.4 billion in 2025, representing an increase of 22.1% as compared to the prior year. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth."
| 指标 | FY2022 | FY2023 | FY2024 | FY2025 | 趋势 |
|---|---|---|---|---|---|
| 营收 | $79.99B | $85.16B | $88.82B | $94.19B | +6.0% |
| 毛利润 | $55.39B | $58.61B | $61.35B | $63.94B | +4.2% |
| 营业利润 | $21.01B | $22.01B | $21.25B | $25.60B | +20.5% |
| 净利润 | $17.94B | $35.15B | $14.07B | $26.80B | 波动 |
| EBITDA | $26.61B | $23.32B | $24.78B | $41.05B | +65.7% |
| 毛利率 | 69.2% | 68.8% | 69.1% | 67.9% | -1.2pp |
净利润因分拆收益、大额诉讼费用和并购相关事项逐年剧烈波动。FY2023的跳升反映Kenvue分拆；FY2024的下滑反映滑石粉和解准备金；FY2025正常化。
二、Intra-Cellular Therapies收购和商誉激增
FY2025资产负债表的决定性事件是2025年4月2日完成的Intra-Cellular Therapies收购。现金流摘要："Cash flow used for investing activities of $23.6 billion was primarily due to: (Dollars in billions) $(4.8) additions to property, plant and equipment (17.5) acquisitions, net of cash acquired."
收购把CAPLYTA带入组合，MD&A把它列为独立的神经科学产品："CAPLYTA (3) 700 * *"——部分年度贡献$7亿。根据结案披露，Intra-Cellular交易对价$146亿。
| 资产负债表 | FY2024 | FY2025 | 变化 |
|---|---|---|---|
| 现金 | $24.11B | $19.71B | $(4.40B) |
| 短期投资 | $0.41B | $0.39B | 持平 |
| 总资产 | $180.10B | $199.21B | +$19.11B |
| 商誉 | $44.20B | $48.77B | +$4.57B |
| 其他无形资产 | $37.62B | $50.40B | +$12.78B |
| 总债务 | $36.63B | $47.93B | +$11.30B |
| 长期债务 | $30.65B | $39.44B | +$8.79B |
| 股东权益 | $71.49B | $81.54B | +$10.05B |
Intra-Cellular交易直接增加了约$128亿无形资产（CAPLYTA产品权利），要求强生发行约$113亿的额外债务。商誉增长10%，无形资产增长34%。
三、现金流：$245亿运营，支持充足
| 指标 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| 经营现金流 | $21.19B | $22.79B | $24.27B | $24.53B |
| 资本开支 | $(4.01B) | $(5.01B) | $(6.21B) | $(5.22B) |
| 自由现金流 | $17.18B | $17.78B | $18.06B | $19.31B |
| CFFO / 净利润 | 1.18 | 0.65 | 1.73 | 0.92 |
| FCF / 净利润 | 0.96 | 0.51 | 1.28 | 0.72 |
10-K："Cash flow from operations of $24.5 billion was the result of: $26.8 Net Earnings; 10.4 non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs, charges for acquired in-process research and development and deferred tax provision partially offset by net gain on sale of assets/businesses; (6.2) an increase in other current and non-current assets; (5.7) a decrease in other current and non-current liabilities; 2.4 an increase in accounts payable and accrued liabilities; (3.2) an increase in accounts receivable and inventories."
应收和存货增长的$32亿是A2关注标记的直接来源。CFFO/NI 0.92对强生历史来说偏紧——公司通常运行在1.0以上——反映了FY2025的营运资本消耗。
四、18项排雷检查
收入质量
| # | 检查项 | 结果 | 说明 |
|---|---|---|---|
| A1 | 应收周转天数 | ✅ | DSO 67天，同比+6天 |
| A2 | 应收 vs 营收增速 | ⚠️ | 应收增长15.7%超过营收增长6.0% |
| A3 | 营收 vs 现金流背离 | ✅ | 营收+6.0%，CFFO+1.1% |
A2关注：应收从$148.4亿增长到$171.8亿（+15.7%）而营收增长6.0%。差距部分来自Intra-Cellular整合（应收余额加入合并账本），部分来自营运资本扩张。DSO从61天扩张到67天——在制药批发商正常周期内但方向不对。
费用质量
| # | 检查项 | 结果 | 说明 |
|---|---|---|---|
| B1 | 存货异常 | ✅ | 存货+14.0% vs COGS+10.1% |
| B2 | 资本开支异常 | ✅ | 资本开支-15.9% vs 营收+6.0% |
| B3 | 费用率 | ✅ | SG&A/毛利润 = 37.0% |
| B4 | 毛利率异常 | ✅ | 毛利率67.9%，-1.2pp |
现金流质量
| # | 检查项 | 结果 | 说明 |
|---|---|---|---|
| C1 | 现金流 vs 利润 | ✅ | CFFO/NI = 0.92 |
| C2 | 自由现金流 | ✅ | FCF $193亿，FCF/NI = 0.72 |
| C3 | 应计比率 | ✅ | 应计比率 = 1.1% |
| C4 | 现金覆盖债务 | ❌ | 现金$201亿仅覆盖债务$479亿的42% |
C4失败：$201亿现金加短期投资对抗$479亿总债务产生42%覆盖率。以每年$193亿FCF，公司可以在不紧张的情况下偿还和减少债务，但机械比率失败。
资产负债表
| # | 检查项 | 结果 | 说明 |
|---|---|---|---|
| D1 | 商誉+无形资产 | ❌ | $992亿 = 净资产122% |
| D2 | 杠杆率 | ✅ | 债务/EBITDA = 1.2x |
| D3 | 软资产增长 | ⚠️ | 其他资产增长25.9% vs 营收6.0% |
| D4 | 资产减值 | N/A | 无减值数据 |
D1失败：商誉$487.7亿加其他无形资产$504.0亿 = $991.7亿，等于$815.4亿权益基数的122%。绝对数字仅FY2025就增长$174亿。债务/EBITDA 1.2x非常健康——杠杆问题是商誉相对权益，不是债务相对盈利。
D3关注：其他非流动资产增长25.9%，因Intra-Cellular整合增加了新的资产负债表项目。
并购风险
| # | 检查项 | 结果 | 说明 |
|---|---|---|---|
| E1 | 并购后现金流 | ✅ | 并购后FCF为正 |
| E2 | 商誉暴增 | ✅ | 商誉+无形同比变化21% |
E2接近阈值：商誉+无形同比增长21%，低于30%暴增阈值但已升高。继续大型并购会将其推入关注区域。
Beneish M-Score
| # | 检查项 | 结果 | 说明 |
|---|---|---|---|
| F1 | M-Score | ✅ | -2.26（< -2.22），不太可能是操纵者 |
M-Score -2.26刚好位于-2.22阈值上——是10家公司集中最薄的一次通过。DSRI分量（由应收激增驱动）正把分数拉向边缘。
五、10-K原文中的关键风险
1. 竞争和失去专利独占权。 10-K："The Company's businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company's earnings... For the Company's Innovative Medicine businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic, biosimilar and other competing products and enter the market." STELARA在FY2025 41%的下滑是这一风险的当前证据。
2. 制造中断和供应链。 "Interruptions and delays in manufacturing operations could adversely affect the Company's business, sales and reputation. The Company's manufacturing of products requires the timely delivery of sufficient amounts of complex, high-quality components and materials."
3. 并购整合和执行风险。 10-K："The Company may also experience operational and financial risk in connection with acquisitions if we are unable to fully identify potential risks and liabilities associated with acquired businesses or products, successfully integrate operations and employees, and successfully identify and realize synergies with existing businesses."
4. 美国创新医药回扣准备金（关键审计事项#1）。 PwC："A significant portion of the liability related to rebates is from the sale of pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $13.0 billion as of December 28, 2025." 这$130亿的回扣准备金是资产负债表上最大的估计之一，任何变化都直接通过营收流动。
5. 滑石粉诉讼或有事项（关键审计事项#2）。 PwC："a significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSON'S Baby Powder." 10-K指出："For these matters, management is unable to estimate the possible loss or range of loss beyond the amounts accrued."
6. Medicare Part D重新设计和定价压力。 MD&A明确把"Medicare Part D重新设计的影响"列为对包括ERLEADA和IMBRUVICA在内的多个产品的拖累。
7. 批发商集中。 "In 2025, the Company utilized three wholesalers distributing products for both segments that represented approximately 21.8%, 15.5% and 11.1% of the total gross revenues." 约48%的强生总营收通过仅三家分销商流动（麦克森/McKesson、Cencora和Cardinal Health）。
六、Altman Z-Score和F-Score
| 模型 | 分数 | 解读 |
|---|---|---|
| Altman Z-Score | **1.91** | 灰色区间（1.10-2.60） |
| F-Score (Dechow) | **1.40** | 低于平均的错报风险 |
Z-Score 1.91位于灰色区间中部。高商誉对权益比和营运资本时序把分数从单看经营现金流画像的水平拉低。
七、总结
| # | 检查项 | 结果 |
|---|---|---|
| A1-A3 | 收入质量 | ✅⚠️✅ |
| B1-B4 | 费用质量 | ✅✅✅✅ |
| C1-C4 | 现金流质量 | ✅✅✅❌ |
| D1-D4 | 资产负债表 | ❌✅⚠️ N/A |
| E1-E2 | 并购风险 | ✅✅ |
| F1 | Beneish M-Score | ✅ |
评级：F。两项失败（现金 vs 债务、商誉+无形）由$175亿的Intra-Cellular Therapies收购驱动。
强生的F评级追踪的是一个具体决定的直接财务后果：2025年4月$146亿收购Intra-Cellular Therapies。这一笔交易增加了约$128亿无形资产、将商誉+无形推到$992亿（权益的122%），并要求$113亿的增量债务，把现金/债务覆盖率降到42%。
底层业务质量仍然高：肿瘤学增长22%（由DARZALEX、CARVYKTI和多发性骨髓瘤系列驱动）；医疗科技增长6.1%（Shockwave整合）；FCF达到$193亿；债务/EBITDA 1.2x（对投资级制药来说深度健康）；M-Score -2.26刚好通过操纵阈值。STELARA生物类似药侵蚀（-41.3%）是有意义的逆风，但TREMFYA 40.5%的增长正在部分填补缺口。
根据10-K自己的风险因素和PwC的关键审计事项，真正的风险是：（1）$130亿美国回扣准备金估计；（2）滑石粉诉讼或有事项（PwC明确指出超出现有应计的部分无法估计）；（3）免疫学组合进一步的生物类似药侵蚀；（4）Medicare Part D重新设计对制药定价的压力。盈利质量风险可控——F评级捕捉的是并购对资产负债表的调整，不是运营恶化。
财报是起点，不是终点。
⚠️ **免责声明**：本报告基于Johnson & Johnson 2025 10-K年报原文（SEC EDGAR）及Yahoo Finance公开财务数据，运用排雷框架进行分析，不构成任何投资建议。投资有风险，决策需自行判断。
数据来源：SEC EDGAR 10-K (Filed 2026-02-11) + Yahoo Finance
审计师：PricewaterhouseCoopers LLP（无保留意见，2项关键审计事项）